FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease
Publishing timestamp: 2023-04-25 13:52:01
Summary
The FDA has granted accelerated approval for Biogen's ALS drug, tofersen, which treats a rare and aggressive form of the disease. However, further studies are required to verify its clinical benefits. The drug specifically targets a form of ALS in people with mutations in a specific gene, which causes a protein called SOD1 to accumulate to toxic levels, damaging the nervous system and leading to the development of ALS. The drug's approval could lead to new research on how to target the genetic cause of ALS, which afflicts an estimated 5,000 new people in the US every year.
Sentiment: NEUTRAL
Keywords: biotech and pharmaceuticals, drug approvals, breaking news, pharmaceuticals, health care industry, business news, science, ionis pharmaceuticals inc, breaking news: business, fda, medication, biogen inc, biotechnology,
Source: https://www.cnbc.com/2023/04/25/fda-grants-accelerated-approval-biogen-als-drug.html